Working... Menu
Trial record 14 of 15 for:    Trebananib | Recruiting, Active, not recruiting, Completed Studies | Cancer | Phase 2

AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00853372
Recruitment Status : Active, not recruiting
First Posted : March 2, 2009
Last Update Posted : November 6, 2018
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : August 8, 2011
  Estimated Study Completion Date : December 17, 2019
  Certification/Extension First Submitted : November 2, 2015